
Opinion|Videos|March 25, 2024
Widening the Therapeutic Window in The Management of Parkinson’s Disease
Expert neurologists discuss strategies to widen the therapeutic window of Parkinson’s disease and options available to treat dyskinesia, providing better control of Parkinson’s disease.
Advertisement
Episodes in this series
Timecodes:
1:20 Long-term challenges
2:58 Fluctuations in benefits
6:35 Therapeutic window
11:40 Amantadine ER for PD
14:33 Dyskinesia and treatment
18:18 Amantadine patients
23:14 Amantadine formulations
27:59 Early treatment & future
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Patients Treated With REGENXBIO’s DMD Gene Therapy RGX-202 Exceed Expected Disease Trajectory on NSAA
2
Phase 3 VALOR Data Further Supports Tofersen’s Impact on ALS Disease Progression, Survival
3
Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1
4
sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis
5





























